Phase II Study of Gemcitabine and Oxaliplatin in the Management of Metastatic Pancreatic Cancers With Low Expression of ERCC1 (Excision Repair Cross-complementation Group 1)
Interventional
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
6 month overall survival
6 months
No
Jared D Acoba, MD
Principal Investigator
University of Hawaii Cancer Research Center
United States: Institutional Review Board
CRCH0904
NCT01524575
January 2012
January 2014
Name | Location |
---|---|
University of Hawaii | Honolulu, Hawaii 96813 |